DOV 216303

Drug Profile

DOV 216303

Alternative Names: DOV 216,303

Latest Information Update: 21 Apr 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer DOV Pharmaceutical
  • Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 07 Dec 2006 Merck and DOV Pharmacueticals terminate their licensing agreement for DOV 216303; DOV regains all rights
  • 05 Oct 2005 Data from a media release have been added to the adverse events and Affective disorders therapeutic trials sections
  • 09 Aug 2004 Merck licensed the exclusive worldwide rights to DOV 216303 for the treatment of depression, anxiety and addiction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top